SIETES :: 93212 citas

Resultados de la búsqueda por ANTAGONISTAS DE LOS LEUCOTRIENOS REFINAR BÚSQUEDA

1.

Rausch C, Hoffmann F. Prescribing medications of questionable benefit prior to death: a retrospective study on older nursing home residents with and without dementia in Germany. Eur J Clin Pharmacol 2020;76:877-85. [Ref.ID 103645]

2.

Anónimo. In brief: Neuropsychiatric events with montelukast. Med Lett Drugs Ther 2020;62:65. [Ref.ID 103638]

3.

Anónimo. FDA requires boxed warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. Risks may include suicidal thoughts or actions. U.S. Food and Drug Administration 2020:4 de marzo. [Ref.ID 103559]

4.

Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. JAMA 2018;319:12 de junio. [Ref.ID 102780]

5.

Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]

6.

Law SWY, Wong AYS, Anand S, Wong ICK, Chan EW. Neurospychiatric events associated with leukotriene-modifying agents: a systematic review. Drug Saf 2018;41:marzo. [Ref.ID 102559]

7.

Henriksen DP, Davidsen JR, Laursen CB, Christiansen A, Damkier P, Hallas J, Pottegård A. Montelukast use — A 19-year nationwide drug utilisation study. Eur J Clin Pharmacol 2017;73:1297-304. [Ref.ID 102083]

8.

Aldea Perona A, García-Sáiz M, Sanz Álvarez E. Psychiatric disorders and montelukast in children: a disproportionality analysis of the VigiBase. Drug Saf 2016;39:69-78. [Ref.ID 100084]

9.

Rudmik L, Soler ZM. Medical therapies for adult chronic sinusitis: a systematic review. JAMA 2015;314:926-39. [Ref.ID 99516]

10.

Loymans RJB, Gemperli A, Cohen J, Rubinstein SM, Sterk PJ, Reddel HK, Jüni P, Ter Riet G. Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations: network meta-analysis. BMJ 2014;348:g3009. [Ref.ID 98004]

11.

Anónimo. Comportements violents envers autrui sous l'effet de médicaments. Prescrire 2014;34:110-3. [Ref.ID 97126]

12.

Anónimo. Montelukast - Neuropsychiatric risks. Australian Prescriber 2013;4:1. [Ref.ID 95148]

13.

Anónimo. Genes after LABA response. Prescribing Advice for GPs 2013:8 de enero. [Ref.ID 94621]

14.

Anónimo. Long-acting beta2 agonists for childhood asthma. Australian Prescriber 2012;35:111-3. [Ref.ID 93160]

15.

Parle J, Ross N, Jones J. Investigating beneficial drug reactions. BMJ 2012;344:35. [Ref.ID 92186]

16.

Ducharme F. Leukotriene receptor antagonists as first line or add-on treatment for asthma. BMJ 2011;343:705-6. [Ref.ID 91735]

17.

Ducharme FM. Leukotriene receptor antagonists as first line or add-on treatment for asthma. BMJ 2011;343:d5314. [Ref.ID 91466]

18.

Schumock GT, Lee TA, Joo MJ, Valuck RJ, Stayner LT, Gibbons RD. Association between leukotriene-modifying agents and suicide: what is the evidence?. Drug Saf 2011;34:533-44. [Ref.ID 90892]

19.

Reuben A, Koch DG, Lee WM, Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010;52:2065-76. [Ref.ID 89970]

20.

Cumming J, Mays N, Daubé J. How New Zealand has contained expenditure on drugs. BMJ 2010;340:1224-6. [Ref.ID 88636]